Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Related Articles by Review for PubMed (Select 20235888)

1.

Lymphangioleiomyomatosis and TSC2-/- cells.

Darling TN, Pacheco-Rodriguez G, Gorio A, Lesma E, Walker C, Moss J.

Lymphat Res Biol. 2010 Mar;8(1):59-69. doi: 10.1089/lrb.2009.0031. Review.

2.

Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).

Kwiatkowski DJ.

Lymphat Res Biol. 2010 Mar;8(1):51-7. doi: 10.1089/lrb.2009.0013. Review.

3.
4.

Metastasis of benign tumor cells in tuberous sclerosis complex.

Henske EP.

Genes Chromosomes Cancer. 2003 Dec;38(4):376-81. Review.

PMID:
14566858
5.

Lymphangioleiomyomatosis and tuberous sclerosis complex.

Chorianopoulos D, Stratakos G.

Lung. 2008 Jul-Aug;186(4):197-207. doi: 10.1007/s00408-008-9087-5. Epub 2008 Apr 12. Review.

PMID:
18408969
6.

Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Krymskaya VP.

Proc Am Thorac Soc. 2008 Jan 1;5(1):119-26. Review.

7.

Clinical and molecular insights into lymphangioleiomyomatosis.

Steagall WK, Taveira-DaSilva AM, Moss J.

Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S49-66. Review.

PMID:
16457017
8.

Tuberous sclerosis complex and DNA repair.

Habib SL.

Adv Exp Med Biol. 2010;685:84-94. Review.

PMID:
20687497
9.
10.

Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.

Yu J, Parkhitko AA, Henske EP.

Proc Am Thorac Soc. 2010 Feb;7(1):48-53. doi: 10.1513/pats.200909-104JS. Review.

11.

Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.

Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP.

Am J Respir Cell Mol Biol. 2007 Apr;36(4):398-408. Epub 2006 Nov 10. Review.

12.

Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.

Goncharova EA, Krymskaya VP.

J Cell Biochem. 2008 Feb 1;103(2):369-82. Review.

PMID:
17541983
13.

Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.

Astrinidis A, Henske EP.

Oncogene. 2005 Nov 14;24(50):7475-81. Review.

PMID:
16288294
14.

A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis.

Sato T, Seyama K, Kumasaka T, Fujii H, Setoguchi Y, Shirai T, Tomino Y, Hino O, Fukuchi Y.

J Intern Med. 2004 Aug;256(2):166-73. Review.

PMID:
15257730
15.

LAM cells biology and lymphangioleiomyomatosis.

Grzegorek I, Drozdz K, Podhorska-Okolow M, Szuba A, Dziegiel P.

Folia Histochem Cytobiol. 2013;51(1):1-10. doi: 10.5603/FHC.2013.001. Review.

16.

Tuberous sclerosis as an underlying basis for infantile spasm.

Yeung RS.

Int Rev Neurobiol. 2002;49:315-32. Review.

PMID:
12040899
17.

[Current understanding and perspectives of lymphangioleiomyomatosis].

Seyama K, Ando K, Hoshika Y, Suzuki Y, Takekawa H.

Nihon Rinsho. 2013 Jun;71(6):1103-8. Review. Japanese.

PMID:
23855221
18.

Extrapulmonary lymphangioleiomyomatosis and lymphangiomatous cysts in tuberous sclerosis complex.

Torres VE, Björnsson J, King BF, Kumar R, Zincke H, Edell ES, Wilson TO, Hattery RR, Gomez MR.

Mayo Clin Proc. 1995 Jul;70(7):641-8. Review.

PMID:
7791386
19.

Lymphangioleiomyomatosis: a disease involving the lymphatic system.

Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T.

Lymphat Res Biol. 2010 Mar;8(1):21-31. doi: 10.1089/lrb.2009.0018. Review.

PMID:
20235884
20.

Therapeutic targeting of mTOR in tuberous sclerosis.

Sampson JR.

Biochem Soc Trans. 2009 Feb;37(Pt 1):259-64. doi: 10.1042/BST0370259. Review.

PMID:
19143643
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk